$COGT
Cogent Biosciences, Inc.

2020 Q1 Form 10-Q Financial Statement

#000156459020024313 Filed on May 11, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019 Q1
Revenue $7.031M $15.29M $3.053M
YoY Change 130.3% 301.79% 37.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.670M $2.690M $2.490M
YoY Change 47.39% 31.86% 134.91%
% of Gross Profit
Research & Development $9.498M $10.35M $12.40M
YoY Change -23.42% -3.9% 52.33%
% of Gross Profit
Depreciation & Amortization $300.0K $310.0K $330.0K
YoY Change -9.09% -11.43% 6.45%
% of Gross Profit
Operating Expenses $9.498M $13.05M $12.40M
YoY Change -23.42% 1.87% 52.33%
Operating Profit -$6.141M $2.240M -$11.84M
YoY Change -48.14% -124.88% 69.5%
Interest Expense $50.00K $60.00K $150.0K
YoY Change -66.67% -85.37% 87.5%
% of Operating Profit 2.68%
Other Income/Expense, Net $47.00K $0.00 $150.0K
YoY Change -68.67% -100.0% -40.24%
Pretax Income -$6.090M $2.300M -$11.69M
YoY Change -47.9% -126.71% 73.44%
Income Tax
% Of Pretax Income
Net Earnings -$6.094M $2.297M -$11.69M
YoY Change -47.87% -126.69% 73.59%
Net Earnings / Revenue -86.67% 15.02% -382.93%
Basic Earnings Per Share $0.07 -$0.39
Diluted Earnings Per Share -$808.8K $0.07 -$0.39
COMMON SHARES
Basic Shares Outstanding 30.61M 30.66B 30.08B
Diluted Shares Outstanding 31.20B 30.08B

Balance Sheet

Concept 2020 Q1 2019 Q4 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.60M $37.40M $67.10M
YoY Change -55.89% -52.42% 107.1%
Cash & Equivalents $30.86M $37.42M $59.11M
Short-Term Investments $0.00 $8.000M
Other Short-Term Assets $1.600M $1.200M $800.0K
YoY Change 100.0% 71.43% -38.46%
Inventory
Prepaid Expenses
Receivables $0.00 $2.000M $2.040M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $31.19M $40.59M $69.90M
YoY Change -55.39% -49.89% 98.43%
LONG-TERM ASSETS
Property, Plant & Equipment $1.570M $1.865M $2.963M
YoY Change -47.01% -42.63% -24.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $427.0K $846.0K
YoY Change 53.66% 1.91% 101.91%
Total Long-Term Assets $7.754M $8.832M $11.38M
YoY Change -31.86% 79.33% 38.98%
TOTAL ASSETS
Total Short-Term Assets $31.19M $40.59M $69.90M
Total Long-Term Assets $7.754M $8.832M $11.38M
Total Assets $38.94M $49.42M $81.28M
YoY Change -52.09% -42.48% 87.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $628.0K $3.183M $1.836M
YoY Change -65.8% 109.55% -40.45%
Accrued Expenses $6.900M $7.900M $6.200M
YoY Change 11.29% 43.64% 195.24%
Deferred Revenue $841.0K $1.315M $16.94M
YoY Change -95.03% -92.67%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.250M $13.25M $26.35M
YoY Change -64.89% -46.89% 14.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.000M $4.400M $5.600M
YoY Change -28.57% 528.57% 21.74%
Total Long-Term Liabilities $4.000M $4.400M $5.600M
YoY Change -28.57% 528.57% 21.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.250M $13.25M $26.35M
Total Long-Term Liabilities $4.000M $4.400M $5.600M
Total Liabilities $13.24M $17.66M $31.99M
YoY Change -58.62% -31.26% 16.26%
SHAREHOLDERS EQUITY
Retained Earnings -$130.0M -$123.9M -$103.8M
YoY Change 25.29% 34.58% 61.45%
Common Stock $155.7M $155.7M $153.0M
YoY Change 1.73% 2.2% 5001.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.70M $31.76M $49.29M
YoY Change
Total Liabilities & Shareholders Equity $38.94M $49.42M $81.28M
YoY Change -52.09% -42.48% 87.22%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019 Q1
OPERATING ACTIVITIES
Net Income -$6.094M $2.297M -$11.69M
YoY Change -47.87% -126.69% 73.59%
Depreciation, Depletion And Amortization $300.0K $310.0K $330.0K
YoY Change -9.09% -11.43% 6.45%
Cash From Operating Activities -$7.893M -$8.440M -$11.52M
YoY Change -31.47% -6.43% 44.32%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K $42.00K
YoY Change -100.0% -44.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $14.99M
YoY Change -100.0% -100.0% 149.83%
Cash From Investing Activities $0.00 -$10.00K $14.95M
YoY Change -100.0% -100.07% 152.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $38.00K $11.00K
YoY Change 245.45% -60.71%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 73.00K 0.000 11.00K
YoY Change 563.64% -100.0% -102.06%
NET CHANGE
Cash From Operating Activities -7.893M -8.440M -11.52M
Cash From Investing Activities 0.000 -10.00K 14.95M
Cash From Financing Activities 73.00K 0.000 11.00K
Net Change In Cash -7.820M -8.450M 3.443M
YoY Change -327.13% -232.45% -232.88%
FREE CASH FLOW
Cash From Operating Activities -$7.893M -$8.440M -$11.52M
Capital Expenditures $0.00 -$10.00K $42.00K
Free Cash Flow -$7.893M -$8.430M -$11.56M
YoY Change -31.72% -6.54% 43.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 umrx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
6123000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
13172000
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
14894000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6141000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11841000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
47000
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
150000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
47000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
150000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6094000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-11691000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30136749
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30083006
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
10000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6094000
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1581000
CY2020Q1 us-gaap Assets Current
AssetsCurrent
31185000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
427000
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1167000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
40591000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5285000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2000000
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
155657000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123892000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
31762000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49423000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1658000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-129986000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
25702000
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
31000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38939000
CY2020Q1 us-gaap Assets
Assets
38939000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1619000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9250000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
628000
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3987000
CY2020Q1 us-gaap Liabilities
Liabilities
13237000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4929000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1570000
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1255000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4413000
CY2019Q4 us-gaap Assets
Assets
49423000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3183000
CY2019Q4 umrx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
7131000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
841000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30821892
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30663054
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30821892
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30663054
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7031000
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3053000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60369000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9498000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12403000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3674000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2491000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11681000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
35000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
262000
CY2020Q1 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
808000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
507000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
60234000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
726000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
49290000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-6094000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-11691000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
295000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
330000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
769000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
726000
CY2019Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-1000
CY2020Q1 umrx Noncash Consideration Received From Customer
NoncashConsiderationReceivedFromCustomer
808000
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
49000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2000000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
372000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
414000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
17000
CY2020Q1 umrx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-356000
CY2019Q1 umrx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-334000
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-427000
CY2019Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
427000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2555000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
317000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1008000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
696000
CY2020Q1 umrx Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-387000
CY2019Q1 umrx Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-352000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-474000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1014000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7893000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11518000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
14992000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14950000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
38000
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11000
CY2020Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
35000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7820000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3443000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38679000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56926000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30859000
CY2020Q1 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
43
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. <font style="color:#000000;">The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our condensed consolidated financial statements as of and for the three months ended March 31, 2020; however, actual results could differ from those estimates and there may be changes to our estimates in future periods.</font></p>
CY2019 umrx Deficiency Letter From Listing Qualifications Department Notifying Period
DeficiencyLetterFromListingQualificationsDepartmentNotifyingPeriod
P30D
CY2019Q4 umrx Minimum Bid Price Of Common Stock
MinimumBidPriceOfCommonStock
1.00
CY2019 umrx Initial Period To Regain Compliance With Minimum Bid Price Rule
InitialPeriodToRegainComplianceWithMinimumBidPriceRule
P180D
CY2019 umrx Additional Period To Regain Compliance With Minimum Bid Price Rule
AdditionalPeriodToRegainComplianceWithMinimumBidPriceRule
P180D
CY2020Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
487000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
485000
CY2020Q1 umrx Fair Value Assets Transfers Involving Level Three
FairValueAssetsTransfersInvolvingLevelThree
0
CY2020Q1 umrx Fair Value Liabilities Transfers Involving Level Three
FairValueLiabilitiesTransfersInvolvingLevelThree
0
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1185000
CY2020Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2500000
CY2020Q1 umrx Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
3436000
CY2019Q4 umrx Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2987000
CY2020Q1 umrx Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
590000
CY2019Q4 umrx Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
750000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
912000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
894000
CY2020Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6123000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7131000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
769000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
726000
CY2020Q1 us-gaap Purchase Obligation
PurchaseObligation
300000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4459293
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4267697
CY2020Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2019Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2020Q1 us-gaap Severance Costs1
SeveranceCosts1
1700000
CY2020Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
1138000
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
1700000
CY2020Q1 us-gaap Restructuring Reserve
RestructuringReserve
562000

Files In Submission

Name View Source Status
0001564590-20-024313-index-headers.html Edgar Link pending
0001564590-20-024313-index.html Edgar Link pending
0001564590-20-024313.txt Edgar Link pending
0001564590-20-024313-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
umrx-10q_20200331.htm Edgar Link pending
umrx-20200331.xml Edgar Link completed
umrx-20200331.xsd Edgar Link pending
umrx-20200331_cal.xml Edgar Link unprocessable
umrx-20200331_def.xml Edgar Link unprocessable
umrx-20200331_lab.xml Edgar Link unprocessable
umrx-20200331_pre.xml Edgar Link unprocessable
umrx-ex103_142.htm Edgar Link pending
umrx-ex311_124.htm Edgar Link pending
umrx-ex312_123.htm Edgar Link pending
umrx-ex321_121.htm Edgar Link pending
umrx-ex322_122.htm Edgar Link pending